Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma
To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming wi...
Gespeichert in:
| Veröffentlicht in: | Cell biochemistry and biophysics 2012, Vol.62 (1), p.257-265 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 265 |
|---|---|
| container_issue | 1 |
| container_start_page | 257 |
| container_title | Cell biochemistry and biophysics |
| container_volume | 62 |
| creator | Lu, Xue-chun Yang, Bo Yu, Rui-li Chi, Xiao-hua Tuo, Shuai Tuo, Chao-wei Zhu, Hong-li Wang, Yao Jiang, Chao-guang Fu, Xiao-bing Yang, Yang Liu, Yang Yao, Shan-qian Dai, Han-ren Cai, Li-li Li, Bing-jun Han, Wei-dong |
| description | To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10
9
–1 × 10
10
) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (
P
|
| doi_str_mv | 10.1007/s12013-011-9273-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_915628378</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>915628378</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-d7fbc1499a0fab0da8449656baa1d55a430edf20a6ffee6b7f413075765a09293</originalsourceid><addsrcrecordid>eNp9kcFu1DAQhi0EoqXwAFyQxYVeTMeJncTHEgpUrAQS5Rw5yXg3xYm3tiOUc18cR1taCYmebNnffJ7xT8hrDu85QHkWeAY8Z8A5U1mZs-IJOeZSKgZZlT9Ne6gkU1zJI_IihGuALAMhnpOjjCueA8hjclvbYRo6bemPOPcLdYaez9FZt3VzoPUS3a9hQnY59XOHPf06WIue1mhtoMZ5GndIrzzqOOIU1-oL26O3C_2u45COAv09xB39OBgzB6Qb7bdIP7BVQDfLuN-5Ub8kz4y2AV_drSfk56eLq_oL23z7fFmfb1gnII-sL03bcaGUBqNb6HUlhCpk0WrNeym1yAF7k4EujEEs2tKINGQpy0JqUJnKT8i7g3fv3c2MITbjELrUiZ4wTdsoLov0cWWVyNNHyfT7VSUqUJDQt_-g1272U5pj9YFMDa8-foA670LwaJq9H0btl2RaZWVziLJJUTZrlE2Rat7cied2xP6-4m92CcgOQEhX0xb9w8v_t_4BwIuo_g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>915051498</pqid></control><display><type>article</type><title>Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma</title><source>MEDLINE</source><source>SpringerLink Journals</source><creator>Lu, Xue-chun ; Yang, Bo ; Yu, Rui-li ; Chi, Xiao-hua ; Tuo, Shuai ; Tuo, Chao-wei ; Zhu, Hong-li ; Wang, Yao ; Jiang, Chao-guang ; Fu, Xiao-bing ; Yang, Yang ; Liu, Yang ; Yao, Shan-qian ; Dai, Han-ren ; Cai, Li-li ; Li, Bing-jun ; Han, Wei-dong</creator><creatorcontrib>Lu, Xue-chun ; Yang, Bo ; Yu, Rui-li ; Chi, Xiao-hua ; Tuo, Shuai ; Tuo, Chao-wei ; Zhu, Hong-li ; Wang, Yao ; Jiang, Chao-guang ; Fu, Xiao-bing ; Yang, Yang ; Liu, Yang ; Yao, Shan-qian ; Dai, Han-ren ; Cai, Li-li ; Li, Bing-jun ; Han, Wei-dong</creatorcontrib><description>To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10
9
–1 × 10
10
) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (
P
< 0.05); whereas serum levels of β2-microglobulin and LDH were significantly decreased (
P
< 0.05). The lymphoma symptoms were reduced and QOL was improved (
P
< 0.05) in all patients. All patients achieved complete remission at study endpoint. No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.</description><identifier>ISSN: 1085-9195</identifier><identifier>EISSN: 1559-0283</identifier><identifier>DOI: 10.1007/s12013-011-9273-6</identifier><identifier>PMID: 21913005</identifier><language>eng</language><publisher>New York: Humana Press Inc</publisher><subject>Aged ; Aged, 80 and over ; Antibodies, Monoclonal - immunology ; Antibodies, Monoclonal - pharmacology ; beta 2-microglobulin ; Biochemistry ; Biological and Medical Physics ; Biomedical and Life Sciences ; Biophysics ; Biotechnology ; CD3 antigen ; CD3 Complex - immunology ; CD3 Complex - metabolism ; CD56 Antigen - metabolism ; CD8 Antigens - metabolism ; Cell Biology ; Cell survival ; Cells, Cultured ; Cytokine-Induced Killer Cells - immunology ; Cytokine-Induced Killer Cells - transplantation ; double prime B-cell lymphoma ; Female ; gamma -Interferon ; Geriatrics ; Humans ; imaging ; Immunotherapy ; Interferon-gamma - pharmacology ; Interleukin 2 ; Interleukin-2 - pharmacology ; Killer cells ; L-Lactate Dehydrogenase - blood ; Life Sciences ; Lymphocytes ; Lymphoma ; Lymphoma, Large B-Cell, Diffuse - diagnostic imaging ; Lymphoma, Large B-Cell, Diffuse - metabolism ; Lymphoma, Large B-Cell, Diffuse - mortality ; Lymphoma, Large B-Cell, Diffuse - therapy ; Macroglobulins - analysis ; Male ; Middle Aged ; Monoclonal antibodies ; Multimodal Imaging ; Peripheral blood mononuclear cells ; Pharmacology/Toxicology ; Positron-Emission Tomography ; Quality of life ; Remission ; Serum levels ; Side effects ; Survival Analysis ; Tomography, X-Ray Computed ; Transfusion ; Translational Biomedical Research ; Transplantation, Autologous ; Treatment Outcome</subject><ispartof>Cell biochemistry and biophysics, 2012, Vol.62 (1), p.257-265</ispartof><rights>Springer Science+Business Media, LLC 2011</rights><rights>Springer Science+Business Media, LLC 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-d7fbc1499a0fab0da8449656baa1d55a430edf20a6ffee6b7f413075765a09293</citedby><cites>FETCH-LOGICAL-c403t-d7fbc1499a0fab0da8449656baa1d55a430edf20a6ffee6b7f413075765a09293</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12013-011-9273-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12013-011-9273-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21913005$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lu, Xue-chun</creatorcontrib><creatorcontrib>Yang, Bo</creatorcontrib><creatorcontrib>Yu, Rui-li</creatorcontrib><creatorcontrib>Chi, Xiao-hua</creatorcontrib><creatorcontrib>Tuo, Shuai</creatorcontrib><creatorcontrib>Tuo, Chao-wei</creatorcontrib><creatorcontrib>Zhu, Hong-li</creatorcontrib><creatorcontrib>Wang, Yao</creatorcontrib><creatorcontrib>Jiang, Chao-guang</creatorcontrib><creatorcontrib>Fu, Xiao-bing</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Liu, Yang</creatorcontrib><creatorcontrib>Yao, Shan-qian</creatorcontrib><creatorcontrib>Dai, Han-ren</creatorcontrib><creatorcontrib>Cai, Li-li</creatorcontrib><creatorcontrib>Li, Bing-jun</creatorcontrib><creatorcontrib>Han, Wei-dong</creatorcontrib><title>Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma</title><title>Cell biochemistry and biophysics</title><addtitle>Cell Biochem Biophys</addtitle><addtitle>Cell Biochem Biophys</addtitle><description>To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10
9
–1 × 10
10
) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (
P
< 0.05); whereas serum levels of β2-microglobulin and LDH were significantly decreased (
P
< 0.05). The lymphoma symptoms were reduced and QOL was improved (
P
< 0.05) in all patients. All patients achieved complete remission at study endpoint. No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antibodies, Monoclonal - immunology</subject><subject>Antibodies, Monoclonal - pharmacology</subject><subject>beta 2-microglobulin</subject><subject>Biochemistry</subject><subject>Biological and Medical Physics</subject><subject>Biomedical and Life Sciences</subject><subject>Biophysics</subject><subject>Biotechnology</subject><subject>CD3 antigen</subject><subject>CD3 Complex - immunology</subject><subject>CD3 Complex - metabolism</subject><subject>CD56 Antigen - metabolism</subject><subject>CD8 Antigens - metabolism</subject><subject>Cell Biology</subject><subject>Cell survival</subject><subject>Cells, Cultured</subject><subject>Cytokine-Induced Killer Cells - immunology</subject><subject>Cytokine-Induced Killer Cells - transplantation</subject><subject>double prime B-cell lymphoma</subject><subject>Female</subject><subject>gamma -Interferon</subject><subject>Geriatrics</subject><subject>Humans</subject><subject>imaging</subject><subject>Immunotherapy</subject><subject>Interferon-gamma - pharmacology</subject><subject>Interleukin 2</subject><subject>Interleukin-2 - pharmacology</subject><subject>Killer cells</subject><subject>L-Lactate Dehydrogenase - blood</subject><subject>Life Sciences</subject><subject>Lymphocytes</subject><subject>Lymphoma</subject><subject>Lymphoma, Large B-Cell, Diffuse - diagnostic imaging</subject><subject>Lymphoma, Large B-Cell, Diffuse - metabolism</subject><subject>Lymphoma, Large B-Cell, Diffuse - mortality</subject><subject>Lymphoma, Large B-Cell, Diffuse - therapy</subject><subject>Macroglobulins - analysis</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>Multimodal Imaging</subject><subject>Peripheral blood mononuclear cells</subject><subject>Pharmacology/Toxicology</subject><subject>Positron-Emission Tomography</subject><subject>Quality of life</subject><subject>Remission</subject><subject>Serum levels</subject><subject>Side effects</subject><subject>Survival Analysis</subject><subject>Tomography, X-Ray Computed</subject><subject>Transfusion</subject><subject>Translational Biomedical Research</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><issn>1085-9195</issn><issn>1559-0283</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kcFu1DAQhi0EoqXwAFyQxYVeTMeJncTHEgpUrAQS5Rw5yXg3xYm3tiOUc18cR1taCYmebNnffJ7xT8hrDu85QHkWeAY8Z8A5U1mZs-IJOeZSKgZZlT9Ne6gkU1zJI_IihGuALAMhnpOjjCueA8hjclvbYRo6bemPOPcLdYaez9FZt3VzoPUS3a9hQnY59XOHPf06WIue1mhtoMZ5GndIrzzqOOIU1-oL26O3C_2u45COAv09xB39OBgzB6Qb7bdIP7BVQDfLuN-5Ub8kz4y2AV_drSfk56eLq_oL23z7fFmfb1gnII-sL03bcaGUBqNb6HUlhCpk0WrNeym1yAF7k4EujEEs2tKINGQpy0JqUJnKT8i7g3fv3c2MITbjELrUiZ4wTdsoLov0cWWVyNNHyfT7VSUqUJDQt_-g1272U5pj9YFMDa8-foA670LwaJq9H0btl2RaZWVziLJJUTZrlE2Rat7cied2xP6-4m92CcgOQEhX0xb9w8v_t_4BwIuo_g</recordid><startdate>2012</startdate><enddate>2012</enddate><creator>Lu, Xue-chun</creator><creator>Yang, Bo</creator><creator>Yu, Rui-li</creator><creator>Chi, Xiao-hua</creator><creator>Tuo, Shuai</creator><creator>Tuo, Chao-wei</creator><creator>Zhu, Hong-li</creator><creator>Wang, Yao</creator><creator>Jiang, Chao-guang</creator><creator>Fu, Xiao-bing</creator><creator>Yang, Yang</creator><creator>Liu, Yang</creator><creator>Yao, Shan-qian</creator><creator>Dai, Han-ren</creator><creator>Cai, Li-li</creator><creator>Li, Bing-jun</creator><creator>Han, Wei-dong</creator><general>Humana Press Inc</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QL</scope><scope>7T5</scope><scope>7T7</scope><scope>7TK</scope><scope>7TM</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>2012</creationdate><title>Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma</title><author>Lu, Xue-chun ; Yang, Bo ; Yu, Rui-li ; Chi, Xiao-hua ; Tuo, Shuai ; Tuo, Chao-wei ; Zhu, Hong-li ; Wang, Yao ; Jiang, Chao-guang ; Fu, Xiao-bing ; Yang, Yang ; Liu, Yang ; Yao, Shan-qian ; Dai, Han-ren ; Cai, Li-li ; Li, Bing-jun ; Han, Wei-dong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-d7fbc1499a0fab0da8449656baa1d55a430edf20a6ffee6b7f413075765a09293</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antibodies, Monoclonal - immunology</topic><topic>Antibodies, Monoclonal - pharmacology</topic><topic>beta 2-microglobulin</topic><topic>Biochemistry</topic><topic>Biological and Medical Physics</topic><topic>Biomedical and Life Sciences</topic><topic>Biophysics</topic><topic>Biotechnology</topic><topic>CD3 antigen</topic><topic>CD3 Complex - immunology</topic><topic>CD3 Complex - metabolism</topic><topic>CD56 Antigen - metabolism</topic><topic>CD8 Antigens - metabolism</topic><topic>Cell Biology</topic><topic>Cell survival</topic><topic>Cells, Cultured</topic><topic>Cytokine-Induced Killer Cells - immunology</topic><topic>Cytokine-Induced Killer Cells - transplantation</topic><topic>double prime B-cell lymphoma</topic><topic>Female</topic><topic>gamma -Interferon</topic><topic>Geriatrics</topic><topic>Humans</topic><topic>imaging</topic><topic>Immunotherapy</topic><topic>Interferon-gamma - pharmacology</topic><topic>Interleukin 2</topic><topic>Interleukin-2 - pharmacology</topic><topic>Killer cells</topic><topic>L-Lactate Dehydrogenase - blood</topic><topic>Life Sciences</topic><topic>Lymphocytes</topic><topic>Lymphoma</topic><topic>Lymphoma, Large B-Cell, Diffuse - diagnostic imaging</topic><topic>Lymphoma, Large B-Cell, Diffuse - metabolism</topic><topic>Lymphoma, Large B-Cell, Diffuse - mortality</topic><topic>Lymphoma, Large B-Cell, Diffuse - therapy</topic><topic>Macroglobulins - analysis</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>Multimodal Imaging</topic><topic>Peripheral blood mononuclear cells</topic><topic>Pharmacology/Toxicology</topic><topic>Positron-Emission Tomography</topic><topic>Quality of life</topic><topic>Remission</topic><topic>Serum levels</topic><topic>Side effects</topic><topic>Survival Analysis</topic><topic>Tomography, X-Ray Computed</topic><topic>Transfusion</topic><topic>Translational Biomedical Research</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lu, Xue-chun</creatorcontrib><creatorcontrib>Yang, Bo</creatorcontrib><creatorcontrib>Yu, Rui-li</creatorcontrib><creatorcontrib>Chi, Xiao-hua</creatorcontrib><creatorcontrib>Tuo, Shuai</creatorcontrib><creatorcontrib>Tuo, Chao-wei</creatorcontrib><creatorcontrib>Zhu, Hong-li</creatorcontrib><creatorcontrib>Wang, Yao</creatorcontrib><creatorcontrib>Jiang, Chao-guang</creatorcontrib><creatorcontrib>Fu, Xiao-bing</creatorcontrib><creatorcontrib>Yang, Yang</creatorcontrib><creatorcontrib>Liu, Yang</creatorcontrib><creatorcontrib>Yao, Shan-qian</creatorcontrib><creatorcontrib>Dai, Han-ren</creatorcontrib><creatorcontrib>Cai, Li-li</creatorcontrib><creatorcontrib>Li, Bing-jun</creatorcontrib><creatorcontrib>Han, Wei-dong</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Immunology Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Cell biochemistry and biophysics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lu, Xue-chun</au><au>Yang, Bo</au><au>Yu, Rui-li</au><au>Chi, Xiao-hua</au><au>Tuo, Shuai</au><au>Tuo, Chao-wei</au><au>Zhu, Hong-li</au><au>Wang, Yao</au><au>Jiang, Chao-guang</au><au>Fu, Xiao-bing</au><au>Yang, Yang</au><au>Liu, Yang</au><au>Yao, Shan-qian</au><au>Dai, Han-ren</au><au>Cai, Li-li</au><au>Li, Bing-jun</au><au>Han, Wei-dong</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma</atitle><jtitle>Cell biochemistry and biophysics</jtitle><stitle>Cell Biochem Biophys</stitle><addtitle>Cell Biochem Biophys</addtitle><date>2012</date><risdate>2012</risdate><volume>62</volume><issue>1</issue><spage>257</spage><epage>265</epage><pages>257-265</pages><issn>1085-9195</issn><eissn>1559-0283</eissn><abstract>To evaluate the effectiveness and safety of autologous cytokine-induced killer (CIK) cells in elderly patients with diffuse large B-cell lymphoma. Peripheral blood mononuclear cells (PBMC) were isolated from nine elderly patients with diffuse large B-cell lymphoma. PBMCs were augmented by priming with interferon gamma (IFN-γ) followed by IL-2 and monoclonal antibody (mAb) against CD3. Autologous CIK cells (range 5 × 10
9
–1 × 10
10
) were then infused back to individual patients; infusion was repeated every 4 weeks for 32 weeks (eight cycles). Patients were assessed for changes in lymphocyte subgroup, tumor-related biological parameters, imaging characteristics, the condition of remission, quality of life (QOL), and survival. Prior to CIK infusion, two patients were in complete remission and seven patients were in partial remission. After autologous CIK cell transfusions, the proportion of CD3+, CD3+CD8+, and CD3+CD56+ cells were significantly increased compared with baseline (
P
< 0.05); whereas serum levels of β2-microglobulin and LDH were significantly decreased (
P
< 0.05). The lymphoma symptoms were reduced and QOL was improved (
P
< 0.05) in all patients. All patients achieved complete remission at study endpoint. No adverse reactions were reported. Autologous CIK cell immunotherapy is safe and efficacious for the treatment of elderly patients with diffuse large B-cell lymphoma.</abstract><cop>New York</cop><pub>Humana Press Inc</pub><pmid>21913005</pmid><doi>10.1007/s12013-011-9273-6</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1085-9195 |
| ispartof | Cell biochemistry and biophysics, 2012, Vol.62 (1), p.257-265 |
| issn | 1085-9195 1559-0283 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_915628378 |
| source | MEDLINE; SpringerLink Journals |
| subjects | Aged Aged, 80 and over Antibodies, Monoclonal - immunology Antibodies, Monoclonal - pharmacology beta 2-microglobulin Biochemistry Biological and Medical Physics Biomedical and Life Sciences Biophysics Biotechnology CD3 antigen CD3 Complex - immunology CD3 Complex - metabolism CD56 Antigen - metabolism CD8 Antigens - metabolism Cell Biology Cell survival Cells, Cultured Cytokine-Induced Killer Cells - immunology Cytokine-Induced Killer Cells - transplantation double prime B-cell lymphoma Female gamma -Interferon Geriatrics Humans imaging Immunotherapy Interferon-gamma - pharmacology Interleukin 2 Interleukin-2 - pharmacology Killer cells L-Lactate Dehydrogenase - blood Life Sciences Lymphocytes Lymphoma Lymphoma, Large B-Cell, Diffuse - diagnostic imaging Lymphoma, Large B-Cell, Diffuse - metabolism Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - therapy Macroglobulins - analysis Male Middle Aged Monoclonal antibodies Multimodal Imaging Peripheral blood mononuclear cells Pharmacology/Toxicology Positron-Emission Tomography Quality of life Remission Serum levels Side effects Survival Analysis Tomography, X-Ray Computed Transfusion Translational Biomedical Research Transplantation, Autologous Treatment Outcome |
| title | Clinical Study of Autologous Cytokine-Induced Killer Cells for the Treatment of Elderly Patients with Diffuse Large B-Cell Lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T00%3A45%3A42IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20Study%20of%20Autologous%20Cytokine-Induced%20Killer%20Cells%20for%20the%20Treatment%20of%20Elderly%20Patients%20with%20Diffuse%20Large%20B-Cell%20Lymphoma&rft.jtitle=Cell%20biochemistry%20and%20biophysics&rft.au=Lu,%20Xue-chun&rft.date=2012&rft.volume=62&rft.issue=1&rft.spage=257&rft.epage=265&rft.pages=257-265&rft.issn=1085-9195&rft.eissn=1559-0283&rft_id=info:doi/10.1007/s12013-011-9273-6&rft_dat=%3Cproquest_cross%3E915628378%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=915051498&rft_id=info:pmid/21913005&rfr_iscdi=true |